Rapid sequencing of the mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility by Streicher, Elizabeth M. et al.
Rapid Sequencing of the Mycobacterium tuberculosis pncA Gene for
Detection of Pyrazinamide Susceptibility
Elizabeth M. Streicher,a Kashmeel Maharaj,b Talita York,a Carel Van Heerden,c Marinus Barnard,a,d Andreas Diacon,a,d
Carl M. Mendel,e Marlein E. Bosman,f Juli A. Hepple,a Alexander S. Pym,b Robin M. Warren,a Paul D. van Heldena
DST/NRF Centre of Excellence for Biomedical Tuberculosis Research/MRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of
Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africaa; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School
of Medicine, University of KwaZulu-Natal, Durban, South Africab; Central Analytical Facilities, Stellenbosch University, Stellenbosch, South Africac; Division of Medical
Physiology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africad; TB Alliance, New York, New
York, USAe; National Health Laboratory Service, Cape Town, South Africaf
We developed a pyrazinamidase gene DNA-sequencing method to rapidly identify pyrazinamide resistance-causing mutations
in GenoLyse-treated, smear-positive sputum specimens. The sensitivity and specificity were 90.9 and 100%, respectively, com-
pared to those of MGIT drug susceptibility testing, after the exclusion of synonymous mutations and nonsynonymous mutations
previously associated with susceptibility to pyrazinamide.
Tuberculosis (TB) clinical trials are planned for the evaluationof new treatment regimens that include pyrazinamide (PZA);
however, culture-based methods for the detection of PZA resis-
tance are complicated because: pyrazinamidase (PZase) is active at
low pH only, results are influenced by inoculum size, and the
assays are difficult and time-consuming (1, 2). Alternative meth-
ods to rapidly screen for PZA susceptibility need to be evaluated.
Point mutations in the pncA gene, which encodes PZase, are the
primary mechanism of resistance to PZA (3, 4); however, muta-
tions and/or polymorphisms occur across the entire length of the
gene, and thus, sequencing of the entire pncA gene is necessary to
capture all of the possible mutations (5). Here we evaluated pncA
DNA sequencing to detect PZA resistance-conferring mutations
directly in clinical specimens.
To determine the diagnostic performance characteristics of
pncA gene sequencing, a set of 85 of 167 stored, GenoLyse-treated
specimens from the NC-002 clinical trial (TB Alliance) were se-
lected because these specimens also had MGIT PZA drug suscep-
tibility data (Becton, Dickinson and Company, NJ, USA). All 85
GenoLyse-treated specimens had been stored on their pellets,
contrary to the manufacturer’s instructions (Hain Lifescience,
Germany). Ethical approval was obtained from the Health Re-
search Ethics Committee of StellenboschUniversity, Pharma Eth-
ics, University of Witwatersrand and University of Cape Town.
The pncA gene was amplified with primers JpncAs Forward (5=
GGCGTCATGGACCCTATA 3=) and JpncAs Reverse (5= GTGA
ACAACCCGACCCAG 3=). These primers were designed to am-
plify a product of 738 bp that includes the full length of the pncA
gene (561 bp), as well as 80 bp of the upstream sequence and 97 bp
of the downstream sequence. Each reaction mixture (25 l) con-
tained 1 to 2.5 l of template DNA (GenoLyse-treated sputum
specimen), 0.75 M each PCR primer (IDT), 1 buffer, 0.8 mM
deoxynucleoside triphosphates, 0.125l (0.625 U) of HotStarTaq
polymerase (Qiagen, Germany), and 2 M Syto9 green-fluores-
cent nucleic acid stain (Invitrogen, CA, USA). The amplification
protocol consisted of an initial activation step of 95°C for 15 min,
followed by 50 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for
1 min and a final elongation step of 10 min at 72°C. Water was
included as a negative control, while H37Rv DNAwas included as
a positive control. Amplification was confirmed by the detection
of a distinct fluorescent melting curve signature consisting of two
maxima (92°C and 93.5°C, respectively) by high-resolution
melting analysis. Post-PCR cleanup was done with the Agencourt
AMPure XP PCR1 purification system (Agencourt Bioscience
Corporation, Beckman Coulter, Beverly, MA). PCR products
were sequenced in both directions with the JpncAs Forward and
JpncAs Reverse primers. The DNA sequencing reaction was done
on a GeneAmp 9700 thermal cycler (Applied Biosystems, Foster
City, CA, USA) with the following program: 5 min at 94°C, fol-
lowed by 25 cycles of 94°C for 10 s, 55°C for 10 s, and 60°C for 4
min, using the BigDye Terminator v3.1 Cycle Sequencing kit (Ap-
plied Biosystems, Austin, TX, USA). The products were then elec-
trophoresed on an ABI3730xl genetic analyzer (Applied Biosys-
tems, Foster City, CA, USA). Sequences were analyzed on the
BioEdit sequence alignment editor (http://www.mbio.ncsu.edu
/bioedit/bioedit.html) with H37Rv as the reference strain. The
sensitivity and specificity of the DNA sequencing method were
determined with Statistica 7.1.
Table 1 shows that 78 (91.8%) specimens were amplifiable and
gave interpretable DNA sequences. The absence of amplification
in the remaining seven (8.2%) specimens was ascribed to the stor-
age of the GenoLyse extracts on their pellets. pncA sequences were
available for 11 of 13 samples with a resistance phenotype (1 had a
wild-type sequence, and 10 had nonsynonymous mutations) (see
Table S1 in the supplemental material). pncA sequences were
available for 67 of the 72 PZA-susceptible samples (2 had synon-
ymous mutations, 4 had nonsynonymous mutations, and 61 had
wild-type sequences [see Table S1 in the supplemental material]).
Review of the four nonsynonymous mutations showed that they
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had been previously associated with PZA susceptibility or low-
level resistance (V130A, L35R, and T114M) (6–10). Thus, a total
of 77 (98.7%) of the 78 specimens would have been correctly
scored on the basis of an algorithm that incorporates previously
described genotype-phenotype relationships. This translates to a
sensitivity and specificity of 90.9% (95% confidence interval
[CI]  0.739 to 1.079) and 100% (95% CI  1.0), respectively,
assuming that the MGIT susceptibility results were correct. The
negative and positive predictive values were 0.985 and 1.000, re-
spectively.
Our turnaround time for PCR and DNA sequencing was 43 h,
compared to conventional culture’s 26 days (range, 12 to 195
days). This shortened time to diagnosis will ensure that patients
with a high risk of PZA resistance (multidrug-resistant TB [MDR-
TB]) are not exposed to inappropriate therapy for an extended
period and can be excluded from trials where PZA is central to
therapy.
The diagnostic value of the DNA-sequencing method relies on
our knowledge of the relationship between the genotype and the
phenotype. Review of the current literature shows that 87 to 95%
of the isolates determined phenotypically to be PZA resistant har-
bor nonsynonymous mutations in the pncA gene (5). PZA resis-
tance in the remaining 5 to 13% of the isolates may occur through
mutations in other genes, including the rpsA gene (11, 12) or
could be false positives of the phenotypic assays (2, 13). Inclusion
of the rpsA genemay improve the assay.Mutations in pncA are not
restricted to PZA-resistant isolates, and synonymous and nonsyn-
onymous mutations have been documented in PZA-susceptible
isolates. Pending a full, definitive, quantitative understanding of
the relationship between pncA mutation and PZA susceptibility,
we propose that wild-type sequences should be considered sus-
ceptible with a low risk of PZA resistance through alternative
mechanisms. Mutations in pncA should be considered resistant
unless synonymous or previously proven to not confer resistance.
Two additional limitations were noted. First, correct storage of
GenoLyse DNA extracts is essential for consistent PCR amplifica-
tion. This can be overcome by aspiration of the extracted DNA
into a clean tube, followed by storage at80°C, as recommended
by the manufacturer. Second, the DNA sequencing method was
tested on DNA extracts from smear-positive sputum samples
only, and it is therefore not plausible at this time to extrapolate
these findings to smear-negative sputum samples.
In summary, we have demonstrated that targeted DNA se-
quencing is a simple, rapid, and accurate method for detecting
PZA resistance that is suitable for clinical trials, as well as for
routine testing of MDR-TB cases.
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TABLE 1 Comparison of pncA sequencing results and Bactec MGIT 960
PZA drug susceptibility test results
Bactec MGIT PZA drug susceptibility test
or pncA sequencing result
No. (%) of
samples
PZA resistant (n 13)
pncA nonsynonymous mutation 10 (76.9)
pncA wild type 1 (7.7)
PCR negative 2 (15.4)
PZA susceptible (n 72)
pncA wild type 61 (84.7)
pncA synonymous mutation 2 (2.8)
pncA nonsynonymous mutation 4a (5.6)
PCR negative 5 (6.9)
a All previously associated with low-level PZA phenotypic resistance (6–10).
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